TY  - JOUR
AU  - Sendker, Stephanie
AU  - Schneider, Markus
AU  - Antoniou, Evangelia
AU  - Neumann, Daniel
AU  - Niktoreh, Naghmeh
AU  - Dirksen, Uta
AU  - von Neuhoff, Nils
AU  - Creutzig, Ursula
AU  - Reinhardt, Dirk
AU  - Waack, Katharina
TI  - Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations.
JO  - Blood advances
VL  - 9
IS  - 11
SN  - 2473-9529
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2025-01194
SP  - 2831 - 2841
PY  - 2025
AB  - Therapy-related acute myeloid leukemia (AML; tAML) is one of the most feared therapy-emergent complications. This study aims to determine the clinical and pathological significance and define therapeutic implications and poor prognosticators in pediatric tAML. We analyzed a total of 119 pediatric patients (aged 2-20 years) who were centrally diagnosed with tAML within the Acute Myeloid Leukemia Berlin-Frankfurt-Münster (AML-BFM) study group between 1993 and 2019. Compared with de novo AML, tAML was associated with decreased white blood count and involvement of the central nervous system. Latency to tAML was inversely correlated with age at primary malignancy. Patients with tAML were more likely to have abnormal karyotypes, overrepresenting KMT2A rearrangements, the unfavorable cytogenetics -7/del(7q), as well as complex and monosomal karyotypes, whereas core-binding AML was underrepresented. The occurrence of stratification-relevant molecular genetics was comparable with de novo AML, whereas CEBPAdm was absent in tAML. Survival rates in tAML improved from 10
KW  - Humans
KW  - Child
KW  - Leukemia, Myeloid, Acute: therapy
KW  - Leukemia, Myeloid, Acute: etiology
KW  - Leukemia, Myeloid, Acute: mortality
KW  - Leukemia, Myeloid, Acute: diagnosis
KW  - Adolescent
KW  - Child, Preschool
KW  - Female
KW  - Male
KW  - Young Adult
KW  - Treatment Outcome
KW  - Prognosis
KW  - Neoplasms, Second Primary: therapy
KW  - Neoplasms, Second Primary: mortality
KW  - Neoplasms, Second Primary: diagnosis
KW  - Neoplasms, Second Primary: etiology
KW  - Disease Management
LB  - PUB:(DE-HGF)16
C6  - pmid:39969195
DO  - DOI:10.1182/bloodadvances.2024014728
UR  - https://inrepo02.dkfz.de/record/301924
ER  -